| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -29,792 | -19,976 |
| Depreciation and amortization | 2,415 | 1,561 |
| Provision for bad debts | 32 | 32 |
| Amortization of right-of-use lease assets | 0 | 0 |
| Amortization of discount on short-term investments | 6,685 | 4,541 |
| Stock-based compensation | 23,795 | 15,687 |
| Provision for excess and obsolete inventory | 1,316 | 1,250 |
| Accounts receivable | -5,867 | -1,960 |
| Inventories | 8,257 | 4,302 |
| Prepaid and other assets | -2,064 | -1,742 |
| Accounts payable | -1,577 | -1,491 |
| Accrued expenses and other liabilities | -3,573 | -5,130 |
| Net cash used in operating activities | -14,395 | -13,208 |
| Purchases of property and equipment | 2,693 | 2,112 |
| Maturities of short-term investments | 170,000 | 110,000 |
| Purchases of short-term investments | 140,804 | 72,381 |
| Net cash provided by (used in) investing activities | 26,503 | 35,507 |
| Proceeds from issuance of common stock from public offering | 0 | 0 |
| Proceeds from issuance of common stock | 2,895 | 2,764 |
| Payments of debt issuance costs | - | 0 |
| Payments for employee taxes related to stock compensation | -2,060 | -1,418 |
| Principal payments on finance lease liabilities | 35 | 16 |
| Payments of deferred offering costs | 0 | 0 |
| Net cash provided by financing activities | 800 | 1,330 |
| Effect of foreign exchange rate on cash, cash equivalents and restricted cash | 18 | 20 |
| Net increase in cash, cash equivalents and restricted cash | 12,926 | 23,649 |
| Cash and cash equivalents at beginning of period | 17,456 | - |
| Cash and cash equivalents at end of period | 30,382 | - |
RxSight, Inc. (RXST)
RxSight, Inc. (RXST)